<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942550</url>
  </required_header>
  <id_info>
    <org_study_id>880526</org_study_id>
    <nct_id>NCT02942550</nct_id>
  </id_info>
  <brief_title>Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients</brief_title>
  <acronym>MOVEMENT</acronym>
  <official_title>Methylnaltrexone as a Method to imprOVE Platelet Inhibition of Ticagrelor in Morphine-treated Patients With ST-segMENT Elevation Myocardial Infarction: a Prospective, Single Blinded Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the impact of the peripheral opioid antagonist methylnaltrexone on&#xD;
      the onset of effect of ticagrelor in morphine treated patients with ST elevation myocardial&#xD;
      infarction (STEMI). Half of the participants will receive methylnaltrexone, while the other&#xD;
      half will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rate of drug absorption in the gastro-intestinal tract is often determined by the rate of&#xD;
      gastric emptying. Morphine treatment, which is frequently given in order to relieve pain in&#xD;
      patients with STEMI, is known to delay gastric emptying, and has indeed emerged as a&#xD;
      predictor of delayed/poor antiplatelet response in patients receiving oral prasugrel or&#xD;
      ticagrelor.&#xD;
&#xD;
      In recent years, morphine has been found to delay the onset of oral P2Y12-inhibitors. To&#xD;
      counteract this, the investigators hypothesized that an opioid antagonist may be used. The&#xD;
      opioid antagonist naloxone has previously been shown to reduce the morphine induced delay in&#xD;
      gastric emptying However, naloxone crosses the blood-brain barrier (BBB) and reduces the pain&#xD;
      relieving effects of morphine. In contrast, the morphine antagonist methylnaltrexone has a&#xD;
      reduced passage over the BBB and acts primarily as a peripheral morphine antagonist without&#xD;
      affecting the morphine-mediated central analgesic effects.&#xD;
&#xD;
      The aim of the planned study is to evaluate whether methylnaltrexone bromide may reduce the&#xD;
      morphine induced delay in onset of platelet inhibition after a loading dose of 180 mg&#xD;
      ticagrelor in morphine treated patients with STEMI undergoing primary percutaneous coronary&#xD;
      intervention (PCI), where a rapid and adequate platelet inhibition after the administration&#xD;
      of ticagrelor is crucial. As morphine is an inclusion criterion, all patients included in the&#xD;
      study will be on morphine treatment. Thus, morphine treatment is not an intervention to be&#xD;
      administered as part of the protocol. Stratification according to inferior and&#xD;
      anterior/lateral STEMI will be perform to avoid imbalance in the location of myocardial&#xD;
      infarction between the groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High on-treatment platelet reactivity (HPR)</measure>
    <time_frame>Two hours after the injection of either active drug or placebo</time_frame>
    <description>HPR defined as platelet reactivity index (PRI) ≥50% using VASP analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with serious adverse events</measure>
    <time_frame>Within 48 hours after drug administration</time_frame>
    <description>Serious AE is any untoward medical occurrence that at any dose:&#xD;
Results in death.&#xD;
Is life-threatening at the time of the event.&#xD;
Requires inpatient hospitalization.&#xD;
Requires prolongation of existing hospitalization.&#xD;
Results in persistent or significant disability/incapacity.&#xD;
Is a congenital anomaly/birth defect.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High on-treatment platelet reactivity</measure>
    <time_frame>One hour after the injection of either active drug or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in ticagrelor and AR-C124910XX concentrations</measure>
    <time_frame>One and two hours after the injection of either active drug or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient pain according to visual analog scale</measure>
    <time_frame>One and two hours after the injection of either active drug or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in ticagrelor and AR-C124910XX concentrations between patients with inferior STEMI and patients with anterior/lateral STEMI.</measure>
    <time_frame>One and two hours after the injection of either active drug or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in high on-treatment platelet reactivity (HPR) between patients with inferior STEMI and patients with anterior/lateral STEMI.</measure>
    <time_frame>One and two hours after the injection of either active drug or placebo</time_frame>
    <description>HPR defined as platelet reactivity index (PRI) ≥50% using VASP analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>STEMI</condition>
  <condition>Morphine</condition>
  <condition>Ticagrelor</condition>
  <condition>Methylnaltrexone</condition>
  <arm_group>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone bromide (Relistor®).</intervention_name>
    <arm_group_label>Methylnaltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 9mg/mL</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of STEMI&#xD;
&#xD;
          -  Administration of a 180 mg loading dose ticagrelor&#xD;
&#xD;
          -  Analgesic treatment with intravenous morphine pre-PCI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac arrest&#xD;
&#xD;
          -  Body weight &gt; 114kg&#xD;
&#xD;
          -  Vomiting after intake of ticagrelor loading dose&#xD;
&#xD;
          -  Use of Naloxone before inclusion or during sampling period&#xD;
&#xD;
          -  Inability to understand study outline and instructions&#xD;
&#xD;
          -  Methylnaltrexone bromide contraindication&#xD;
&#xD;
          -  Age &lt;18 years; 8) Women in fertile age&#xD;
&#xD;
          -  Administration of ticagrelor during the week before inclusion&#xD;
&#xD;
          -  Treatment with Cangrexal&#xD;
&#xD;
          -  Ongoing long-term opioid treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Tornvall, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf Jensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nawzad Saleh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loghman Henareh, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset (Stockholm South General Hospital)</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jan van der Linden</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Methylnaltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will only be published on a group level.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

